Show simple item record

dc.contributor.advisorMcBride, Ali
dc.contributor.authorMcGinnis, Stephen
dc.contributor.authorPham, Ann
dc.date.accessioned2019-05-03T20:09:05Z
dc.date.available2019-05-03T20:09:05Z
dc.date.issued2018
dc.identifier.urihttp://hdl.handle.net/10150/632196
dc.descriptionClass of 2018 Abstracten_US
dc.description.abstractSpecific Aims In patients with current or previous infection with the hepatitis B virus (HBV), immunosuppressive effects of rituximab can lead to viral reactivation of HBV. Screening patients for HBV prior to initiating rituximab is important in preventing reactivation. This project aims to examine the effects of a policy change on the rate of HBV screening. Methods A local system-wide policy change was implemented in April 2014 that provides criteria and requirements for HBV screening prior to the initiation of rituximab therapy. In this project, a retrospective chart review was performed to analyze the impact of the policy change on the rate of appropriate HBV screening. Only patients receiving rituximab for non-oncology indications were included in this project. All patients who received rituximab for cancer were excluded. Main Results In total, 253 patients were initiated on rituximab for non-oncology indications during the study period. The rate of screening for HBsAg increased from 24% before the policy change to 31% after the policy change (p=0.34). Similarly the rate of screening for HBcAb increased from 20% to 26% (p=0.42). Conclusions Although the findings were not statistically significant, the project remains important because similar studies have not targeted non-oncology indications for rituximab. This shows that policies with clearly stated criteria and requirements could potentially improve the rates of appropriate HBV screening across all medical subspecialties.en_US
dc.language.isoen_USen_US
dc.publisherThe University of Arizona.en_US
dc.rightsCopyright © is held by the author.en_US
dc.subjecthepatitis B virusen_US
dc.subjectHBVen_US
dc.subjectrituximaben_US
dc.subjectscreeningen_US
dc.subjectreactivationen_US
dc.subject.meshHepatitis B Virusen_US
dc.subject.meshRituximaben_US
dc.subject.meshDiagnostic Screening Programsen_US
dc.titleThe impact of a comprehensive policy change on the number of patients appropriately screened for HBV prior to administration of rituximaben_US
dc.typetexten_US
dc.typeElectronic Reporten_US
dc.contributor.departmentCollege of Pharmacy, The University of Arizonaen_US
dc.description.collectioninformationThis item is part of the Pharmacy Student Research Projects collection, made available by the College of Pharmacy and the University Libraries at the University of Arizona. For more information about items in this collection, please contact Jennifer Martin, Associate Librarian and Clinical Instructor, Pharmacy Practice and Science, jenmartin@email.arizona.edu.en_US


This item appears in the following Collection(s)

Show simple item record